tesaglitazar has been researched along with Atherosclerosis in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Camejo, G; Havekes, LM; Jukema, JW; Lundholm, E; Princen, HM; Rensen, PC; van der Hoorn, JW | 1 |
| Halabi, CM; Sigmund, CD | 1 |
| Boesten, LS; Camejo, G; Emeis, JJ; Havekes, LM; Jukema, JW; Kooistra, T; Lundholm, E; van Vlijmen, BJ; Zadelaar, AS | 1 |
| Chait, A; Chira, EC; Haw, A; McMillen, TS; O'Brien, KD; Wang, S; Wight, TN | 1 |
1 review(s) available for tesaglitazar and Atherosclerosis
| Article | Year |
|---|---|
Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications.
Topics: Alkanesulfonates; Animals; Atherosclerosis; Clinical Trials as Topic; Clofibric Acid; Humans; Hypertension; Mice; Mice, Knockout; Models, Animal; Phenylpropionates; PPAR gamma; Thiazolidinediones | 2005 |
3 other study(ies) available for tesaglitazar and Atherosclerosis
| Article | Year |
|---|---|
The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice.
Topics: Alkanesulfonates; Animals; Aortic Valve; Apolipoprotein E3; Atherosclerosis; Cholesterol Ester Transfer Proteins; Cholesterol, HDL; Cholesterol, VLDL; Female; Humans; Inflammation; Mice; Mice, Transgenic; Mutation; Phenylpropionates; PPAR alpha; PPAR gamma | 2009 |
Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice.
Topics: Alkanesulfonates; Animals; Apolipoprotein E3; Apolipoproteins E; Atherosclerosis; Biomarkers; Blood Vessels; Cell Adhesion; Cholesterol; Cholesterol, Dietary; Collagen; Dietary Fats; Female; Hypercholesterolemia; Inflammation; Insulin Resistance; Lipids; Lipoproteins; Macrophages; Mice; Mice, Transgenic; Monocytes; NF-kappa B; Phenylpropionates; PPAR alpha; PPAR gamma | 2006 |
Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice.
Topics: Alkanesulfonates; Animals; Atherosclerosis; Blood Glucose; Cholesterol; Female; Lipids; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Models, Statistical; Phenylpropionates; PPAR alpha; PPAR gamma; Receptors, LDL | 2007 |